Show simple item record

dc.contributor.authorGonzález-Martín, Antonio
dc.contributor.authorPothuri, Bhavana
dc.contributor.authorVergote, Ignace
dc.contributor.authorDePont Christensen, René
dc.contributor.authorGraybill, Whitney
dc.contributor.authorMirza, Mansoor R
dc.contributor.authorMcCormick, Colleen
dc.contributor.authorLorusso, Domenica
dc.contributor.authorHoskins, Paul
dc.contributor.authorFreyer, Gilles
dc.contributor.authorBaumann, Klaus
dc.contributor.authorJardon, Kris
dc.contributor.authorRedondo, Andrés
dc.contributor.authorMoore, Richard G
dc.contributor.authorVulsteke, Christof
dc.contributor.authorO'Cearbhaill, Roisin E
dc.contributor.authorLund, Bente
dc.contributor.authorBackes, Floor
dc.contributor.authorBarretina-Ginesta, Pilar
dc.contributor.authorHaggerty, Ashley F
dc.contributor.authorRubio-Pérez, Maria J
dc.contributor.authorShahin, Mark S
dc.contributor.authorMangili, Giorgia
dc.contributor.authorBradley, William H
dc.contributor.authorBruchim, Ilan
dc.contributor.authorSun, Kaiming
dc.contributor.authorMalinowska, Izabela A
dc.contributor.authorLi, Yong
dc.contributor.authorGupta, Divya
dc.contributor.authorMonk, Bradley J
dc.date.accessioned2020-02-01T00:28:42Z
dc.date.available2020-02-01T00:28:42Z
dc.date.issued2019-09-28
dc.identifier.citationGonzález-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., … Monk, B. J. (2019). Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 381(25), 2391–2402. https://doi.org/10.1056/nejmoa1910962 ‌en_US
dc.identifier.issn0028-4793
dc.identifier.pmid31562799
dc.identifier.doi10.1056/NEJMoa1910962
dc.identifier.urihttp://hdl.handle.net/10150/636841
dc.description.abstractNiraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown.en_US
dc.description.sponsorshipGlaxoSmithKlineen_US
dc.language.isoenen_US
dc.publisherMASSACHUSETTS MEDICAL SOCen_US
dc.rightsCopyright © 2019 Massachusetts Medical Society.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.titleNiraparib in Patients with Newly Diagnosed Advanced Ovarian Canceren_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Med, Arizona Oncol US Oncol Networken_US
dc.identifier.journalNEW ENGLAND JOURNAL OF MEDICINEen_US
dc.description.note6 month embargo; published online: 28 September 2019en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleThe New England journal of medicine
dc.source.volume381
dc.source.issue25
dc.source.beginpage2391
dc.source.endpage2402
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
nejmoa1910962.pdf
Size:
432.8Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record